The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer.
Cancers (Basel)
; 14(15)2022 Jul 25.
Article
in En
| MEDLINE
| ID: mdl-35892879
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Cancers (Basel)
Year:
2022
Type:
Article
Affiliation country:
Australia